



















































































































































































4,493	(8.7%) 1,423	(23.2%) 953	(25.0%) 1,562	(23.3%) 192	(0.6%) 363	(13.7%)
Female 25,559
(49.4%)





72.8	(12.3) 73.2	(11.0) 71.6	(12.0) 71.0	(12.9) 73.5	(12.3) 70.5	(13.5)
≥ 80	years-old17,200
(33.3%)










	 	 	 	 	 	
Missing	GFR 9,788	(18.9%) 1,249	(20.4%) 839	(22.0%) 1,636	(24.4%) 5,561	(17.2%) 503	(19.0%)
GFR ≥ 60 30,687
(59.4%)





1,198	(19.5%) 577	(15.1%) 1,088	(16.3%) 6,867	(21.1%) 518	(19.6%)
GFR < 30 967	(1.9%) 83	(1.4%) 29	(0.8%) 62	(0.9%) 728	(2.2%) 65	(2.5%)
BMI	groups 	 	 	 	 	 	
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GFR < 30 967	(1.9%) 83	(1.4%) 29	(0.8%) 62	(0.9%) 728	(2.2%) 65	(2.5%)
BMI	groups
(kg/m2)
	 	 	 	 	 	
Missing 12,408
(24.0%)
1,685	(27.5%) 1,138	(29.9%) 2,057	(30.7%) 6,932	(21.4%) 596	(22.5%)
18.5–25
(Normal)
6,701	(13.0%) 676	(11.0%) 416	(10.9%) 735	(11.0%) 4,501	(13.9%) 373	(14.1%)
< 18.5
(Underweight)










2,034	(33.2%) 1,195	(31.4%) 2,115	(31.6%) 10,688
(33.0%)
841	(31.7%)
CHA2DS2VASc 	 	 	 	 	 	
0	or	1
(woman)
4,902	(9.5%) 480	(7.8%) 476	(12.5%) 887	(13.3%) 2,738	(8.4%) 321	(12.1%)
1 3,398	(6.6%) 375	(6.1%) 280	(7.4%) 500	(7.5%) 2,040	(6.3%) 203	(7.7%)
≥ 2 43,390
(83.9%)
5,280	(86.1%) 3,052	(80.1%) 5,307	(79.2%) 27,626
(85.3%)
2,125	(80.2%)
HAS	-	BLED 	 	 	 	 	 	
0 4,166	(8.1%) 540	(8.8%) 509	(13.4%) 903	(13.5%) 1,918	(5.9%) 296	(11.2%)
1–2 29,391
(56.9%)





1,668	(27.2%) 894	(23.4%) 1,548	(23.1%) 13,164
(40.6%)
859	(32.4%)
Comorbidities 	 	 	 	 	 	
Heart	failure 6,133	(11.9%) 866	(14.1%) 439	(11.5%) 783	(11.7%) 3,656	(11.3%) 389	(14.7%)
Peripheral
artery	disease
2,764	(5.3%) 323	(5.3%) 154	(4.0%) 294	(4.4%) 1,801	(5.6%) 192	(7.2%)
Ischemic
heart	disease




2,460	(4.8%) 246	(4.0%) 130	(3.4%) 263	(3.9%) 1,638	(5.1%) 183	(6.9%)
Hypertension 35,144
(68.0%)












6,248	(12.1%) 891	(14.5%) 523	(13.7%) 731	(10.9%) 3,725	(11.5%) 378	(14.3%)
Cancer 13,211
(25.6%)
1,606	(26.2%) 940	(24.7%) 1,698	(25.4%) 8,249	(25.5%) 718	(27.1%)
















9,105	(17.6%) 985	(16.1%) 518	(13.6%) 997	(14.9%) 6,082	(18.8%) 523	(19.7%)
Diuretics 19,051
(36.9%)





































































































99	(23.7%) 19	(15.3%) 39	(37.9%) 33	(22.9%) 5	(41,7%) 3	(8.6%)
Discontinuatio
ns	at	1st	year




























Non-adherence	(< 80%) 145	(38.7%) 222	(52.2%) 139	(27.9%)
Good	adherence	(≥ 80%) 230	(61.3%) 203	(47.8%) 360	(80.1%)










Non-adherence	(< 80%) 27	(32.9%) 33	(66.0%) 17	(18.3%)
Good	adherence	(≥ 80%) 55	(67.1%) 17	(34.0%) 76	(81.7%)
MPR,	median	(IQR) 94.5	(53.4–98.6) 75.1	(71.6–94.7) 99.7	(84.4–99.7)
MPR:	medication	possession	ratio,	IQR:	interquartile	range.
Although	the	measure	of	persistence	for	VKA	should	be	different	to	the	measure	for	DOAC,	in	Fig.	2
we	show	data	for	both	groups	of	anticoagulants	in	order	to	compare	them.	This	figure	shows	Kaplan-
Meier	curves	for	treatment	discontinuation	of	DOAC	and	VKA	in	naive	patients;	there	were	high	DOAC
discontinuation	rates	at	treatment	start	and,	over	time	apixaban	showed	lower	discontinuation	rates.
Discussion
We	included	51,690	new	users	of	OAC	in	this	population-based	cohort	study,	41,146	of	them	had
dispensing	data	available	in	SIDIAP	(79.6%).	Approximately	20%	of	them	patients	initiated	DOAC,
pointing	out	that	VKA	are	still	the	first	therapeutic	option	for	anticoagulation	in	NVAF	in	our	setting,	as
recommended	by	AEMPS.[26]	Most	patients	(83.9%)	had	CHA2DS2VASc	score ≥ 2,	which	is	the
criterion	to	anticoagulate	in	NVAF	patients	according	to	guidelines	[32,	33].	Patients	with	highest	risks
of	stroke	were	those	in	the	groups	of	acenocoumarol	and	apixaban,	as	shown	in	previous	studies	[14,
22,	34].
Therapeutic	adherences	at	implementation	and	persistence	to	OAC	were	assessed	in	those	patients
who	were	adherent	at	initiation	and	started	anticoagulation	treatment	before	2015.	Only	one	third	of
naive	patients	received	DOAC	treatment	during	at	least	one	year	of	follow-up,	for	VKA	the	proportion
was	higher.	Between	them,	rivaroxaban	group	showed	the	highest	percentage	of	patients	with	good
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adherence	at	implementation	(MPR ≥ 80)	and	dabigatran	the	lowest.	Similar	results	were	also	found
by	Forslund	et	al.	[22]	or	by	Beyer-Westendorf	et	al.	[23]	although	this	last	study	only	analysed
rivaroxaban	and	dabigatran.	On	the	opposite,	other	studies	found	higher	MPR	in	apixaban-treated
patients	[14,	35].
Regarding	persistence	to	DOAC	in	naive	patients,	apixaban	showed	higher	discontinuation	rates
during	the	first	month	of	treatment	but	at	one	year,	all	DOAC	showed	similar	rates.	Several	studies
analysed	discontinuation	rates	at	different	times	during	follow-up.	After	one	year,	apixaban	users
were	more	persistent	than	other	DOAC	and	VKA	users	in	the	studies	conducted	by	Forslund	et	al.	[22]
and	Johnson	et	al.	[21]
Other	studies	which	analysed	persistence	in	naive	patients	only	included	dabigatran	and	rivaroxaban.
Rivaroxaban	presented	better	persistence	than	dabigatran	and	VKA	[23,	36].
Manzoor	et	al.	[35]	or	Martínez	et	al.	[37]	studied	all	DOAC	together	as	a	group.	The	first	one	showed
higher	levels	of	persistence	to	DOAC	in	anticoagulant-experienced	patients	over	time.	Martínez	et	al.
found	higher	levels	of	persistence	in	DOAC	versus	VKA	users,	which	slightly	decreased	during	the	first
year	of	follow-up	(from	94.7%	of	persistents	to	DOAC	at	3	months	to	72.9%	at	12	months).
For	anticoagulant-experienced	patients	with	more	than	one	year	of	follow-up	in	our	study,	again
rivaroxaban	showed	the	largest	proportion	of	patients	with	good	adherence	during	implementation.
Only	Manzoor	et	al.	[35]	analysed	MPR	in	non-naive	patients	and	apixaban	showed	higher	MPR	in
apixaban	at	6	months	and	dabigatran	at	9	months.	Discontinuation	rates	in	our	non-naive	patients
were	much	lower	than	for	the	naive	ones;	during	the	first	month	since	treatment	initiation	1.6%
apixaban,	4.9%	rivaroxaban	and	12.6%	dabigatran	patients	discontinued	the	treatment,	and	after	one
year	apixaban	users	showed	higher	persistence	rates	than	dabigatran	and	rivaroxaban	(66.1%	>
64.6%	>	48.5%).	Manzoor	et	al.	[35]	compared	persistence	between	naive	and	non-naive	patients
receiving	DOAC	and	the	last	ones	showed	higher	levels	of	persistence.	Johnson	et	al.	[21]	described
similar	discontinuation	rates	than	for	naive	patients	and	at	the	end-of	follow-up	patients	prescribed
apixaban	showed	improved	persistence	over	dabigatran,	rivaroxaban	and	VKA.
The	differences	in	treatment	persistence	between	naive	and	anticoagulant-experienced	patients	in
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our	study	could	be	motivated	by	a	better	knowledge	of	the	anticoagulation	importance	of	these
patients	who	previously	received	mainly	VKA,	and	they	were	used	to	attend	monthly	to	PHC	centres
for	INR	determination	and	had	optimal	levels	of	drug	adherence.
Suboptimal	adherence	to	anticoagulant	therapy	places	patients	with	AF	at	risk	for	stroke	or	bleeding
complications.	Our	study	concludes	as	most	observational	studies,	that	the	guidelines
recommendations	regarding	anticoagulant	therapy	are	not	routinely	followed	in	clinical	practice,	and
adherence	is	substantially	lower	than	in	clinical	trials	[3,	38].
Some	specific	limitations	in	our	database	are	the	lack	of	association	between	GP’s	prescriptions	and
dispensing	associated	with	these	prescriptions.	This	study	has	missing	data	from	pharmacy	claims
and	for	some	variables	as	it	is	common	in	observational	studies	using	electronic	databases
(information	bias).	The	strengths	of	our	study	are	representativeness	for	the	general	population,	with
a	database	that	covers	almost	the	80%	of	the	Catalonian	population,	with	complete	sociodemographic
and	health	records,	long	follow-up,	and	real	clinical	practice	data.
Conclusions
A	total	of	51,690	patients	had	a	new	prescription	of	OAC	during	the	study	period,	8,155	of	them
received	new	dispensings	for	DOAC.
We	measured	persistence	in	22,075	patients	receiving	anticoagulants,	3,425	were	DOAC-treated
patients.
MPR	was	measured	for	DOAC	patients	and	was	higher	for	rivaroxaban,	followed	by	apixaban	and
dabigatran.
Persistence	to	DOAC	was	low	in	our	setting,	which	may	result	in	higher	risk	of	thromboembolic	events.
Discontinuation	rates	were	higher	in	naive	than	in	non-naive	patients.	This	may	be	caused	by	better
knowledge	of	the	importance	of	treatment	adherence	in	patients	who	have	previously	received	VKA,
which	need	a	more	strict	management.
Abbreviations
List	of	abbreviations
AEMPS	Agencia	Española	de	Medicamentos	y	Productos	Sanitarios
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DOAC	Direct	oral	anticoagulants
ECAP	Electronic	health	records	in	PHC
ICS	Catalan	health	institute
MPR	Medication	possession	ratio
NVAF	Non-valvular	atrial	fibrillation
OAC	Oral	anticoagulants
PHC	Primary	healthcare
SD	Standard	deviation
SIDIAP	Information	system	for	research	in	Primary	Care
VKA	Vitamin	K	antagonists
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Figure	1
Flowchart	of	patients	included	in	the	study	NVAF:	non-valvular	atrial	fibrillation,	VKA:
vitamin	K	antagonists
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Figure	2
Discontinuation	of	direct	oral	anticoagulants	and	vitamin	K	antagonists	in	naive	patients
